Alliance for Pandemic Preparedness
May 19, 2020
Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody
Category: Article Summary
Topic: Testing and Treatment
- Pinto et al. describe an antibody(S309) that neutralizes SARS-CoV-2. This antibody was identified from memory B cells of a person infected with SARS-CoV in 2003. The S309 antibody functions by engaging the SARS-CoV-2 spike glycoprotein receptor-binding domain, the region that facilitates the SARS-CoV-2 virus’ entry into host cells.
- These findings can be used to facilitate development of S309-and S309-containing antibody therapies for prophylactic use in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.
Pinto et al. (May18, 2020). Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. https://doi.org/10.1038/s41586-020-2349-y